ALK gene rearrangements have been described in 3–5% of lung adenocarcinomas (ADC), and the presence of dysregulated ALK has been described in at least 18 cancer types (reviewed in 1). Since lung cancer is a common type of cancer, an estimated 70,000 cases of non-small cell lung cancer (NSCLC) which have ALK genomic alterations occur… Read article →
Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3–5% of lung adenocarcinomas (ADC) (2–4, Figure 1), and over 20 ALK fusion partners have been implicated in non-small-cell lung cancer (NSCLC) (5). Thanks to the relatively recent development of small molecule targeted therapies, the ALK oncogene is now targetable using ALK tyrosine kinase inhibitors (TKIs)… Read article →
Impressions from the QIAGEN booth at #ASHG2018 in San Diego. See you in Houston, TX in 2019! https://t.co/j3CQXsGK6E, Jennifer Poitras presents her poster at #ASHG2018 in San Diego on concordance of BRCA1/2 variant classification in… https://t.co/9nNN5M6I9q, Capture all relevant inherited mutations, including CNVs, SNVs, InDels and Fusions, for a range of rare hereditary… https://t.co/jqEeDtAhzP, Dr. Wenbo Xu, Lab Director at True Health Diagnostics, on the challenges faced in next generation sequencing when d… https://t.co/Zil7hj6cXy, Interested in gaining next-generation insights for hereditary disease? Visit the QIAGEN booth #1339 at #ASHG to lea… https://t.co/zhyXkZ7kDP, 
